All News
Filter News
Found 808,690 articles
-
Synta Pharmaceuticals Announces Presentation of Additional Ganetespib Results at American Society of Clinical Oncology
6/6/2011
-
Exelixis, Inc. Cabozantinib Phase 2 Data Demonstrate Encouraging Clinical Activity in Patients with Metastatic Castration-Resistant Prostate Cancer
6/6/2011
-
Myrexis, Inc. Reports Azixa(R) Phase 2 Study Results at 2011 American Society of Clinical Oncology Annual Meeting
6/6/2011
-
Geron Corporation Highlights American Society of Clinical Oncology/American Association for Cancer Research Joint Session: Telomeres and Telomerase in Cancer
6/6/2011
-
Nuvilex Readies Pancreatic Cancer Treatment for Expanded Phase II Clinical Trials
6/6/2011
-
Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company Present Updated Brentuximab Vedotin (SGN-35) Data at American Society of Clinical Oncology Annual Meeting
6/6/2011
-
Endocyte, Inc.'s EC145 Meets Primary Endpoint in Phase 2 Study, Demonstrating 85 Percent (2.3 month) Improvement in Median Progression-Free Survival for Treatment of Platinum Resistant Ovarian Cancer
6/6/2011
-
EntreMed, Inc.'s ENMD-2076 Demonstrates Clinical Activity in Recurrent, Platinum-Resistant Ovarian Cancer Patients
6/6/2011
-
Ligand Pharmaceuticals Inc. Presents Phase IIa Data on Captisol(R)-Enabled, Propylene Glycol-Free Melphalan at American Society of Clinical Oncology 2011
6/6/2011
-
Medivation, Inc. and Astellas Pharma Inc. Announce New Study Results Confirming Clinical Effects and Tolerability of MDV3100 in Advanced Prostate Cancer
6/6/2011
-
Agennix AG Announces New Data From Talactoferrin Phase II Trials in Non-Small Cell Lung Cancer and in Severe Sepsis Presented at American Society of Clinical Oncology Annual Meeting
6/6/2011
-
Cell>Point Presents Phase 2 Clinical Trial Results Comparing its 99mTc-EC-G SPECT Cancer Imaging Agent to FDG PET at Society of Nuclear Medicine Annual Meeting June 7, 2011
6/6/2011
-
Immunomedics, Inc. Reports First Clinical Results of New Antibody-Directed Radiation Therapy for Colorectal Cancer
6/6/2011
-
RXi Pharmaceuticals Announces Positive NeuVaxTM (E75) Phase 2 Efficacy Results After 36 Months of Follow-Up
6/6/2011
-
Adolor Corporation Completes Enrollment in Phase 2 OIC Program
6/6/2011
-
Celator Pharmaceuticals, Inc. Presents Positive Data from Phase 2 Study of CPX-351 at the American Society of Clinical Oncology Meeting
6/6/2011
-
Stemline Therapeutics, Inc. Announces Oral Presentation of Positive Phase I/II Trial Results with Novel Brain Cancer Vaccine at the American Society of Clinical Oncology 2011 Annual Meeting
6/6/2011
-
ZIOPHARM Oncology, Inc. Announces Initial Positive Data Presented at 2011 American Society of Clinical Oncology Annual Meeting from First-Ever Treatment Demonstrating Small Molecule-Controlled Production of Anticancer Protein in Humans
6/6/2011
-
Seattle Genetics, Inc. Presents SGN-75 Clinical Data at American Society of Clinical Oncology Annual Meetingse
6/6/2011
-
Tekmira Pharmaceuticals Corporation's LNP Delivery Technology Enables Proof of RNAi in Man and Clinical Activity
6/6/2011